Insider · CIK 0001643941

ORLOFF JOHN J

Reports to the SEC for 5 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001643941

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-15	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2025-06-10	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2024-09-12	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2021-07-21	ALEXION PHARMACEUTICALS, INC.D Disposition to Issuer	EVP, Research & Development	DDisposition to Issuer	−147K sh	—	—	0
2021-07-14	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+30.6K sh	—	—	117,010
2021-07-14	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+29.5K sh	—	—	146,511
2021-06-08	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−1,957 sh	$177.00	−$346K	86,367
2021-02-28	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+24.5K sh	—	—	88,324
2020-12-16	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+40.7K sh	—	—	85,206
2020-12-16	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−18.1K sh	$157.96	−$2.86M	67,072
2020-12-16	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−3,261 sh	$157.96	−$515K	63,811
2020-12-15	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+40 sh	$93.53	+$3,741.2	63,851
2020-06-08	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−2,784 sh	$114.61	−$319K	44,529
2020-03-02	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−1,396 sh	$90.54	−$126K	47,275
2020-02-28	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+10.9K sh	—	—	48,671
2019-12-15	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+38 sh	$93.86	+$3,566.68	47,313
2019-06-07	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−2,786 sh	$118.61	−$330K	37,791
2019-02-28	ALEXION PHARMACEUTICALS, INC.F Tax Payment	EVP, Research & Development	FTax Payment	−675 sh	$132.92	−$89.7K	31,115
2019-02-28	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+9,428 sh	—	—	40,577
2018-12-15	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+34 sh	$93.01	+$3,162.34	31,149
2018-08-09	NOVELION THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2018-06-08	ALEXION PHARMACEUTICALS, INC.S Sale	EVP, Research & Development	SSale	−2,115 sh	$118.53	−$251K	31,790
2018-02-28	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+8,940 sh	—	—	33,905
2017-07-03	NOVELION THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+9,600 sh	—	—	9,600
2017-06-07	ALEXION PHARMACEUTICALS, INC.A Award	EVP, Research & Development	AAward	+25K sh	—	—	24,965
2016-12-22	NOVELION THERAPEUTICS INC.Stock Option (right to buy)A Award	Director	AAward	+166K sh	—	—	166,020
2016-06-03	Baxalta IncD Disposition to Issuer	See Remarks	DDisposition to Issuer	−96.4K sh	—	—	0
2016-06-03	Baxalta IncStock Option (Right to Buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−21.7K sh	—	—	0
2016-06-03	Baxalta IncStock Option (Right to Buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−88.2K sh	—	—	0
2016-06-03	Baxalta IncStock Option (Right to Buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−82.1K sh	—	—	0
2016-03-03	Baxalta IncA Award	See Remarks	AAward	+56K sh	—	—	97,417
2016-03-03	Baxalta IncF Tax Payment	See Remarks	FTax Payment	−1,408 sh	$39.30	−$55.3K	96,009
2015-07-01	Baxalta IncJ Other	See Remarks	JOther	+40.5K sh	—	—	40,521
2015-07-01	Baxalta IncStock Option (Right to Buy)J Other	See Remarks	JOther	+21.7K sh	—	—	21,667
2015-07-01	Baxalta IncStock Option (Right to Buy)J Other	See Remarks	JOther	+88.2K sh	—	—	88,168
2015-07-01	Baxalta IncStock Option (Right to Buy)A Award	See Remarks	AAward	+82.1K sh	—	—	82,063

Recent filings

Accepted (ET)
Jun 174
ORLOFF JOHN J0001104659-26-075255
SEC(opens sec.gov)
Jun 124
ORLOFF JOHN J0001104659-25-058922
SEC(opens sec.gov)
Sep 164
ORLOFF JOHN J0001104659-24-100339
SEC(opens sec.gov)
Jul 234
ORLOFF JOHN J0000899866-21-000062
SEC(opens sec.gov)
Jul 164
ORLOFF JOHN J0000899866-21-000054
SEC(opens sec.gov)
Jun 94
ORLOFF JOHN J0000899866-21-000050
SEC(opens sec.gov)
Mar 24
ORLOFF JOHN J0000899866-21-000023
SEC(opens sec.gov)
Dec 184
ORLOFF JOHN J0000899866-20-000093
SEC(opens sec.gov)
Jun 94
ORLOFF JOHN J0000899866-20-000063
SEC(opens sec.gov)
Mar 34
ORLOFF JOHN J0000899866-20-000023
SEC(opens sec.gov)
Jun 114
ORLOFF JOHN J0000899866-19-000077
SEC(opens sec.gov)
Mar 54
ORLOFF JOHN J0000899866-19-000048
SEC(opens sec.gov)
Mar 44
ORLOFF JOHN J0000899866-19-000041
SEC(opens sec.gov)

Companies

Address

C/O ZENAS BIOPHARMA, INC. 852 WINTER ST., SUITE 250

WALTHAM, MA, 02451